Home
Boehringer Ingelheim

Boehringer Ingelheim Market Share Analysis for July 2026

Pets and Animals > Pet Food and Supplies

Domainboehringer-ingelheim.com.au

Year Founded1885

Employees> 10001

Annual Revenue> $1B

Boehringer Ingelheim

Boehringer Ingelheim (including company regionals)

boehringer-ingelheim.com.au

See more website traffic and engagement information

Boehringer Ingelheim Revenue up to July 2026 is > 1B

revenue generated by Boehringer Ingelheim top domains

Boehringer Ingelheim top domains revenue over 3 years

Revenue for Boehringer Ingelheim top domains

boehringer-ingelheim.com.au> 1B

See more with Sales Intelligence

Total visits to Boehringer Ingelheim's top domains

Understand Boehringer Ingelheim market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Boehringer Ingelheim's top domains

Analyze Boehringer Ingelheim engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Boehringer Ingelheim's top domains

See how Boehringer Ingelheim keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Boehringer Ingelheim top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Boehringer Ingelheim

These are the website technologies, by industry, used by Boehringer Ingelheim top domains

Conversion & Analytics (7)

Google Analytics

Audio Video Media (4)

YouTube

Social (4)

Google+ Platform

Advertising (3)

DoubleClick

More Technologies

9

See all

News & Signals from Boehringer Ingelheim

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsUniversity of Sydney partners with Boehringer Ingelheim.University of Sydney spinout Kinoxis Therapeutics has announced a strategic partnership and licensing agreement with global pharmaceutical company Boehringer Ingelheim for the development of first-in-class oxytocin-targeting precision psychiatry treatments to improve the quality of life of people living with neuropsychiatric disorders.

NewsBoehringer Ingelheim partners with Kinoxis Therapeutics Pty Ltd.Boehringer Ingelheim is heading out into the surf with Australia's Kinoxis Therapeutics in a $181 million biobucks deal to develop therapies for neuropsychiatric disorders.